Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Finance
EpiCast Report: Dermatophytic Onychomycosis - Epidemiology Forecast to 2022

Global dermatophytic onychomycosis market: Over 59 million cases by 2022


Print article Print article
© companiesandmarkets.com

companiesandmarkets.com
companiesandmarkets.com
2014-03-03 05:55:04 - EpiCast Report: Dermatophytic Onychomycosis - Epidemiology Forecast to 2022 - a new market research report on companiesandmarkets.com

Fungal nail infections pose a global health threat, with over 50 million people suffering from the contagious condition last year. Prevalent cases of dermatophytic onychomycosis (DO) across US, France, Germany, Italy, Spain, UK, and Japan will increase by a further 15% over the next decade, from 51.50 million cases in 2012 to 59.17 million cases by 2022.

Epidemiologists forecast that the US alone will see prevalent cases of DO rise from 31.66 million cases in 2012 to 37.69 million cases by 2022, following a 19.1% increase over the next decade.

The prevalence of DO in the general population across the US, France, Germany, Italy, Spain, and the UK currently ranges from between 2% and 12%.

DO is a fungal

 

 

infection of the nail fold or nail plate, beginning as a white or yellow spot under the tip of the nail, with discoloration and thickening of the nail worsening as the infection spreads deeper, resulting in nail disfigurement and discomfort. DO accounts for around half of all nail diseases in the world, and represents a considerable medical burden. The disease is not life-threatening, but can cause significant pain and discomfort, and the indolent nature of the disease often leads to cases going undiagnosed and untreated for a long period of time, potentially progressing to the point where walking may become difficult or painful.

The contagious nature of this condition means that DO is often contracted through contact with a contaminated surface. Fungal spores shed by infected individuals are commonly found on household floors, public swimming pools, and gym and sports changing facilities. For this reason, members of the same household have a greater risk of contracting the infection, and Japans high forecast for DO prevalence could be attributed to the countrys traditional practice of walking barefoot in the house, as this practice facilitates spread of DO infection.

Immunosuppressed individuals, such as those suffering from HIV infection, diabetes, or cancer, are more susceptible to DO. The risk of contracting DO also becomes more common with advancing age, with disease prevalence being almost tripled in individuals over 50 years of age, perhaps due to their immune system naturally weakening.

Diabetic individuals are particularly predisposed to developing DO, as impaired sensation caused by neuropathy may make individuals less aware of abrasions on their feet, which can easily become a portal of entry for bacterial infections. Poor glycemic control and vascular insufficiency suffered by diabetics also commonly lead to skin infections.

Conversely, healthy athletes also face a high risk of contracting the disease, as airtight sports shoes and sweating feet make the ideal breeding ground for fungal infection. Men are also 30% more likely to be infected with DO than women, possibly due to behavioral factors such as higher rates of trauma to the nails of the hands or feet, as a result of physical activity.

Scope

- The Dermatophytic Onychomycosis (DO) EpiCast Report provides an overview of the risk factors and global trends of DO in the seven major markets (US, France, Germany, Italy, Spain, UK, and Japan).
- It also includes a 10-year epidemiology forecast of the prevalent cases of DO, segmented by sex, and age (15-29 years, 30-49 years, 50-69 years, and 70 years) in these markets.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global DO market.
- Quantify patient populations in the global DO market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for DO therapeutics in each of the markets covered.

Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Market Research Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..

Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..

About Us
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.com’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.


Author:
Mike King
e-mail
Web: www.companiesandmarkets.com
Phone: London: +44 (0) 203 086 8600

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com